Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

被引：0
|
作者：
Makoto Sudo
Tan Min Chin
Seiichi Mori
Ngan B. Doan
Jonathan W. Said
Makoto Akashi
H. Phillip Koeffler
机构：
[1] National University of Singapore,Cancer Science Institute
[2] National University Hospital,Department of Hematology and Oncology
[3] The Cancer Institute,Department of Cancer Genomics
[4] Japanese Foundation for Cancer Research,Department of Pathology and Laboratory Medicine
[5] University of California,Research Center for Radiation Emergency
[6] National Institute of Radiological Sciences,Division of Hematology and Oncology
[7] Cedars-Sinai Medical Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitor (TKI); EGFR; 17-DMAG; Belinostat; Combination chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1325 / 1334
页数：9
相关论文
共 50 条
  • [21] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [22] Chemical Synthesis of Novel DDR1 Inhibitors and Their Activity Against Gefitinib-Resistant Non-Small Cell Lung Cancer
    Xu, Xuemei
    Chen, Siyu
    Sun, Doudou
    Wang, Xuebao
    Xu, Zhouyang
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2025, 51 (01) : 285 - 297
  • [23] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    Chang, John Wen-Cheng
    Chou, Chun-Liang
    Huang, Shiu-Feng
    Wang, Hung-Ming
    Hsieh, Jia-Juan
    Hsu, Todd
    Cheung, Yun-Chung
    LUNG CANCER, 2007, 58 (03) : 414 - 417
  • [24] Apoptotic effect of a single compound derived from natural product in Gefitinib-resistant non-small cell lung cancer cells
    Fan, Xing-Xing
    Wong, Maria Pik
    Cao, Zhi-Wei
    Li, Na
    Wu, Jin-Lin
    Zhou, Hua
    Jiang, Zhi-Hong
    Liu, Liang
    Leung, Elaine Lai-Han
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
    Hidayat, Moulid
    Mitsuishi, Yoichiro
    Takahashi, Fumiyuki
    Tajima, Ken
    Yae, Toshifumi
    Miyahara, Katsumi
    Hayakawa, Daisuke
    Winardi, Wira
    Ihara, Hiroaki
    Koinuma, Yoshika
    Wirawan, Aditya
    Nurwidya, Fariz
    Kato, Motoyasu
    Kobayashi, Isao
    Sasaki, Shinichi
    Takamochi, Kazuya
    Hayashi, Takuo
    Suehara, Yoshiyuki
    Moriyama, Mariko
    Moriyama, Hiroyuki
    Habu, Sonoko
    Takahashi, Kazuhisa
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 19 (04) : 355 - 367
  • [26] Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
    Koizumi, F
    Shimoyama, T
    Taguchi, F
    Saijo, N
    Nishio, K
    INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (01) : 36 - 44
  • [27] Synthesis of Flavokawain B and its Anti-proliferative Activity Against Gefitinib-resistant Non-small Cell Lung Cancer (NSCLC)
    Seo, Young Ho
    Oh, Yong Jin
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2013, 34 (12): : 3782 - 3786
  • [28] Effect of paclitaxel in gefitinib-resistant non-small cell lung cancer (NSCLC) treatment during the COVID-19 pandemic.
    Mohiuddin, Md
    Kasahara, Kazuo
    CLINICAL CANCER RESEARCH, 2020, 27 (06)
  • [29] Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway
    Xie, Ya-Jia
    Gao, Wei-Na
    Wu, Qi-Biao
    Yao, Xiao-Jun
    Jiang, Ze-Bo
    Wang, Yu-Wei
    Wang, Wen-Jun
    Li, Wei
    Hussain, Shahid
    Liu, Liang
    Leung, Elaine Lai-Han
    Fan, Xing-Xing
    PHARMACOLOGICAL RESEARCH, 2020, 159
  • [30] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
12345